Article Information
- Received March 12, 2024
- Revision received May 9, 2024
- Accepted May 24, 2024
- Published online June 4, 2024.
Author Information
- Eduardo Martin-Lopez1,2,
- Bowen Brennan1,2,
- Tianyang Mao3,4,5,
- Natalie Spence1,2,
- Sarah J. Meller1,2,6,
- Kimberly Han1,2,
- Nawal Yahiaoui1,2,
- Chelsea Wang1,2,
- Akiko Iwasaki3,4,5 and
- Charles A. Greer1,2,6
- 1Department of Neurosurgery, Yale University School of Medicine, New Haven, Connecticut 06520-8082
- 2Department of Neuroscience, Yale University School of Medicine, New Haven, Connecticut 06520-8001
- 3Department of Immunobiology, Yale University School of Medicine, The Anlyan Center, New Haven, Connecticut 06520-8043
- 4Yale University School of Public Health, New Haven, Connecticut 06520-0834
- 5Howard Hughes Medical Institute, Chevy Chase, Maryland 20815
- 6Interdepartmental Neuroscience Program, Yale University School of Medicine, New Haven, Connecticut 06520-8074
- Correspondence should be addressed to Charles A. Greer at charles.greer{at}yale.edu or Akiko Iwasaki at akiko.iwasaki{at}yale.edu.
Author contributions
Author contributions: E.M-L., T.M., A.I., and C.A.G. designed research; E.M-L., B.B., N.S., S.J.M., K.H., N.Y., and C.W. performed research; T.M. contributed unpublished reagents/analytic tools; E.M-L., B.B., N.S., S.J.M., K.H., N.Y., C.W., A.I., and C.A.G. analyzed data; E.M-L., T.M., A.I., and C.A.G. wrote the paper.
Disclosures
E.M-L., T.M., B.B., N.S., S.J.M., K.H., N.Y., C.W., and C.A.G. authors declare no competing financial interests. A.I. co-founded RIGImmune, Xanadu Bio, and PanV and is a member of the Board of Directors of Roche Holding and Genentech.
This work was supported by National Institutes of Health–National Institute on Deafness and Other Communication Disorders (NIH-NIDCD) 013791, NIH-NIDCD 016851, NIH-NIDCD 017989, and The Whitehall Foundation to C.A.G. and NIH R01AI157488, the Howard Hughes Medical Institute Collaborative COVID-19 Initiative, and the Howard Hughes Medical Institute Emerging Pathogens Initiative to A.I.; we express our appreciation to Christine Kaliszewski for her technical assistance and all members of the Greer and Iwasaki labs for their discussions.
Funding
HHS | NIH | National Institute on Deafness and Other Communication Disorders (NIDCD)
013791; 016851; 017989HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
157488Howard Hughes Medical Institute (HHMI)
The Whitehall Foundation
Other Version
- You are viewing the most recent version of this article.
- previous version (June 04, 2024).
Article usage
In this issue
